On Wednesday, Aug. 24, David Boothman, PhD, the Robert B. and Virginia Payne Professor of Oncology and Pharmacology, and associate director for translational research, Simmons Cancer Center, UT Southwestern at Dallas, will present “Use of NQ01 bioactivatable drugs for tumor-selective therapy.” Boothman also co-directs the Program in Cell Stress and Cancer Nanomedicine. He was previously awarded the 2012 Pancreatic Cancer Action Network Innovative Grant, funded by the George & June Block Family Foundation, and the 2015 Clinical Continuation Research Grant, funded with the Rising Tide Foundation and Gateway for Cancer Research.
Boothman's research focused on the biochemistry and pharmacology of anticancer drugs, specifically 5-fluoro-deoxycytidine derivatives. The Aug. 24 DCI Seminar Series will be held in the Great Hall at Trent Semans Center. The Hematology Oncology Fellow presentations begins at 7:30 a.m. David Boothman will speak at 8:10 a.m.